BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.